Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT With or Without ADT for Unfavorable Intermediate Risk Prostate Cancer
NCT06397703Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Apr 2024
- Primary completion
- Apr 2030
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of leuprolide, degarelix, tissue-plasminogen activator in prostate cancer (PCa), sponsored by NYU Langone Health. Started Apr 2024; status: recruiting.
02
Drugs
leuprolidedegarelixtissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06397703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397703.